News Release

Enzyme Crystal Structure Reveals "Unexpected" Genome Repair Functions

New Discovery Could Help Improve Some Forms of Chemotherapy

LA JOLLA, CA, April 6, 2006—Scientists at The Scripps Research Institute and Lawrence Berkeley National Laboratory have determined the crystal structure of an enzyme called xeroderma pigmentosum group B (XPB) helicase, identifying several unexpected functions and helping to address important questions about the enzyme's role in DNA transcription and repair. The research illuminated, for the first time, the roles played by the important XPB protein in recognizing blockages in reading the DNA code and in initiating an efficient method of repair. The discovery may be useful in the quest to develop new forms of chemotherapy.

"The results suggest a previously unsuspected mechanism for the repair process," notes project leader John Tainer, who is a professor at Scripps Research, member of Scripps Research's Skaggs Institute for Chemical Biology, and co-principal investigator of the Structural Cell Biology of DNA Repair project, Life Sciences Division, at the Lawrence Berkeley Lab. "We were surprised by the findings."

Noting that this is the first structure of its kind, team member Priscilla Cooper, who is head of Lawrence Berkeley's Department of Molecular Biology and co-principal investigator of the Structural Cell Biology of DNA Repair project, says, "This discovery may be useful in the quest to develop new cancer diagnostic and therapeutic strategies, including the identification of promising new forms of chemotherapy."

The study was published in an advance online version of the journal Molecular Cell.

DNA Repair Machines

All the information for heredity is encoded in DNA molecules that are constantly under attack from sources inside and outside the body—by sunlight, ionizing radiation, other environmental carcinogens, and free radicals from the normal cellular metabolism. Surprisingly, most of this damage comes from the chemical reactions that are the normal processes needed for life, so life is impossible without DNA repair even in the absence of environmental toxins.

DNA damage ranges from one or a few altered nucleotides in a single strand of the double helix, to breaks in one or both strands and crosslinks between the two strands. To prevent accumulation of mutations and the production of altered proteins, cells must deploy an arsenal of repair mechanisms to excise and replace defective nucleotides, reconnect broken strands, and patch up other kinds of damage. As most damage comes from endogenous sources generated by the cellular metabolism, the impact of environmental and other mutagens depends upon the cell's ability to repair DNA damage, and this processes depends upon the accurate assembly of molecular machines for DNA repair such as the newly characterized XPB helicase.

Mutations that cause changes in these machines can block these DNA repair processes or even uncouple their normally coordinated actions to result in cancer and degenerative diseases associated with aging. This relationship is reflected by the extremely high cancer predisposition of individuals with hereditary defects in DNA-repair processes.

In xeroderma pigmentosum patients, for example, exposure to sunlight typically causes hyper-pigmented skin that is dry and parchment-like, and is followed by multiple skin cancers. If carefully shielded from ultraviolet light, for example by window filters and protective clothing, many xeroderma pigmentosum sufferers can lead seemingly normal lives. Xeroderma pigmentosum results from mutations in any one of seven genes, labeled XPA through XPG, which are involved in the well-understood DNA repair mechanism called nucleotide-excision repair.

"XPB was initially identified as the gene responsible for nucleotide-excision repair defects in xeroderma pigmentosumpatients, who are hypersensitive to light and have a dramatically increased risk of skin cancer," says Tainer. "This reflects the fact that XPB plays a key role in unwinding damaged DNA during nucleotide-excision repair, which removes a broad spectrum of DNA lesions, including those caused by exposure to ultraviolet light."

Cockayne Syndrome is another disease of faulty DNA repair—this time of "transcription-coupled repair," which is repair to genes that are actively being transcribed into messenger RNA. Cockayne Syndrome is marked by severe physical and mental retardation — victims have an unusually small brain and fail to grow and develop normally after birth; pronounced wasting usually begins in the first year of life. As they grow older, Cockayne Syndrome sufferers look increasingly aged, with faces marked by sunken eyes. Average life expectancy is only 12 years and few survive their teens. Mutations in three XP-associated genes— XPB, XPD, and XPG — can lead to this syndrome.

A New Model

The research reported by this new study approached the complex repair machinery by looking at a simpler system involving the XPB helicase from an archaea, a single-cell organism analogous to bacteria, in many ways resembling the nucleus or core of human cells. Helicases are enzymes that unwind or separate the strands of the nucleic acid double helix, an action that is critical to transcription and nucleotide excision repair, as well as other cell processes.

Nucleotide excision repair, a critical defense mechanism that removes DNA lesions caused by the mutating effects of sunlight (ultraviolet light) and toxic chemicals is also central  to the success of the anticancer drug cisplatin, since cisplatin works by initiating the process of DNA repair, in turn activating apoptosis or programmed cell death when the repair process fails. "Because chemotherapeutic agents like the chemotherapy drug cisplatin and radiation therapy work by essentially damaging DNA, any new understanding of the DNA repair mechanism could mean potential improvements in the treatment of cancer," Tainer says.

Prior to this study, there were no specific models for how XPB acts in DNA separation either to initiate transcription or to begin nucleotide excision repair. There were also no models for the role that XPB, which is an essential subunit of Transcription Factor IIH (TFIIH) functional assembly complex, might play in changing conformations for TFIIH's alternate roles in either transcription or DNA repair.

The XPB crystal structures developed by the researchers identified unexpected functional domains for XPB. Research Associate Li Fan of Scripps Research, the first author of the study, notes, "We were surprised when we found that XPB contains a domain structurally similar to the mismatch recognition domain of a bacterial DNA repair protein MutS. MutS helps recognize and repair mismatched DNA in E. coli. These two proteins have little sequence similarity. Biochemical assays following this discovery indicate that this domain allows XPB to interact with damaged DNA and enhances its unwinding activity on damaged DNA."

The report suggests that unknown protein and DNA interactions at transcription sites activate XPB within the TFIIH complex to allow it to start the DNA unwinding process.

"Even though TFIIH does not act directly in initial damage recognition, the interaction of XPB with the DNA lesion suggests that XPB plays a role in switching TFIIH from transcription mode to nucleotide excision repair," Tainer says. "The structural biochemistry of XPB that we discovered shows an unexpected molecular mechanism by which XPB plays a key role in determining exactly how TFIIH functions, whether in transcription or repair mode."

Tainer and Li noted that the Lawrence Berkeley National Laboratory provided key technologies for this advance especially the SIBYLS synchrotron beamline at the Berkeley lab's Advanced Light Source. This allowed the use of intense x-rays to visualize the XPB structures and to reveal how the protein can change its shape to recognize damaged DNA and unwind DNA to read its information. Other authors of the paper include Andrew Arvai, Priscilla K. Cooper, Shigenori Iwai, and Fumio Hanaoka.

The study was supported by the Human Frontiers of Science Program, the National Cancer Institute and the U.S. Department of Energy.

About The Scripps Research Institute and Lawrence Berkeley National Laboratory

The Scripps Research Institute, headquartered in La Jolla, California, in 18 buildings on 40 acres overlooking the Pacific Ocean, is one of the world's largest independent, non-profit biomedical research organizations. It stands at the forefront of basic biomedical science that seeks to comprehend the most fundamental processes of life. Scripps Research is internationally recognized for its research into immunology, molecular and cellular biology, chemistry, neurosciences, autoimmune, cardiovascular, and infectious diseases, and synthetic vaccine development. Established in its current configuration in 1961, it employs approximately 3,000 scientists, postdoctoral fellows, scientific and other technicians, doctoral degree graduate students, and administrative and technical support personnel. See the website

Scripps Florida, a 364,000 square-foot, state-of-the-art biomedical research facility, will be built in Palm Beach County. The facility will focus on basic biomedical science, drug discovery, and technology development. Palm Beach County and the State of Florida have provided start-up economic packages for development, building, staffing, and equipping the campus. Scripps Florida now operates with approximately 160 scientists, technicians, and administrative staff at 40,000 square-foot lab facilities on the Florida Atlantic University campus in Jupiter.

Both Lawrence Berkeley National Laboratory and Scripps Research continue the tradition of multidisciplinary scientific teams working together to solve global problems in human health, technology, energy, and the environment. Lawrence Berkeley Lab is a U.S. Department of Energy national laboratory located in Berkeley, California. It conducts unclassified scientific research and is managed by the University of California. Its website can be found at

For more information contact:
Office of Communications
10550 North Torrey Pines Road
La Jolla, California 92037

For more information, contact See More News